Top

Published in:

01-12-2010 | Review

Treatment of complicated intra-abdominal infections in the era of multi-drug resistant bacteria

Authors: T Herzog, AM Chromik, W Uhl

Published in: European Journal of Medical Research | Issue 12/2010

Abstract

The management of severe intra-abdominal infections remains a major challenge facing surgeons and intensive care physicians, because of its association with high morbidity and mortality. Surgical management and intensive care medicine have constantly improved, but in the recent years a rapidly continuing emergence of resistant pathogens led to treatment failure secondary to infections with multi-drug resistant bacteria. In secondary peritonitis the rate of resistant germs at the initial operation is already 30%. The lack of effective antibiotics against these pathogens resulted in the development of new broad-spectrum compounds and antibiotics directed against resistant germs. But so far no "super-drug" with efficacy against all resistant bacteria exists. Even more, soon after their approval, reports on resistance against these novel drugs have been reported, or the drugs were withdrawn from the market due to severe side effects. Since pharmaceutical companies reduced their investigations on antibiotic research, only few new antimicrobial derivates are available.

In abdominal surgery you may be in fear that in the future more and more patients with tertiary peritonitis secondary to multi-drug resistant species are seen with an increase of mortality after secondary peritonitis.

This article reviews the current treatment modalities for complicated intra-abdominal infections with special reference to the antibiotic treatment of complicated intra-abdominal infections with multi-drug resistant species.

Barie PS, Hydo LJ, Eachempati SR: Longitudinal outcomes of intra-abdominal infection complicated by critical illness. Surg Infect (Larchmt) 2004,5(4):365–73. 10.1089/sur.2004.5.365CrossRef

Dellinger EP, Wertz MJ, Meakins JL, et al.: Surgical infection stratification system for intra-abdominal infection. Multicenter trial. Arch Surg 1985,120(1):21–9. 10.1001/archsurg.1985.01390250015003PubMedCrossRef

Finfer S, Bellomo R, Lipman J, et al.: Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med 2004,30(4):589–96. 10.1007/s00134-004-2157-0PubMedCrossRef

Vincent JL, Rello J, Marshall J, et al.: International study of the prevalence and outcomes of infection in intensive care units. Jama 2009,302(21):2323–9. 10.1001/jama.2009.1754PubMedCrossRef

Wittmann DH, Schein M, Condon RE: Management of secondary peritonitis. Ann Surg 1996,224(1):10–8. 10.1097/00000658-199607000-00003PubMedCentralPubMedCrossRef

Myers E, Hurley M, O'Sullivan GC, et al.: Laparoscopic peritoneal lavage for generalized peritonitis due to perforated diverticulitis. Br J Surg 2008,95(1):97–101.PubMedCrossRef

Penninckx FM, Kerremans RP, Lauwers PM: Planned re-laparotomies in the surgical treatment of severe generalized peritonitis from intestinal origin. World J Surg 1983,7(6):762–6. 10.1007/BF01655218PubMedCrossRef

Teichmann W, Wittmann DH, Andreone PA: Scheduled reoperations (etappenlavage) for diffuse peritonitis. Arch Surg 1986,121(2):147–52. 10.1001/archsurg.1986.01400020033002PubMedCrossRef

Solomkin JS, Mazuski JE, Bradley JS, et al.: Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Surg Infect (Larchmt) 2010,11(1):79–109. 10.1089/sur.2009.9930CrossRef

10.

Ingraham AM, Cohen ME, Bilimoria KY, et al.: Comparison of outcomes after laparoscopic versus open appendectomy for acute appendicitis at 222 ACS NSQIP hospitals. Surgery 2010,148(4):625–35. discussion 635–7 10.1016/j.surg.2010.07.025PubMedCrossRef

11.

Farthmann EH, Schoffel U: Epidemiology and patho-physiology of intraabdominal infections (IAI). Infection 1998,26(5):329–34. 10.1007/BF02962266PubMedCrossRef

12.

Calandra T, Cohen J: The international sepsis forum consensus conference on definitions of infection in the intensive care unit. Crit Care Med 2005,33(7):1538–48. 10.1097/01.CCM.0000168253.91200.83PubMedCrossRef

13.

Fridkin SK, Hageman JC, Morrison M, et al.: Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005,352(14):1436–44. 10.1056/NEJMoa043252PubMedCrossRef

14.

Montravers P, Lepape A, Dubreuil L, et al.: Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: results of the French prospective, observational EBIIA study. J Antimicrob Chemother 2009,63(4):785–94. 10.1093/jac/dkp005PubMedCrossRef

15.

Evans HL, Raymond DP, Pelletier SJ, et al.: Diagnosis of intra-abdominal infection in the critically ill patient. Curr Opin Crit Care 2001,7(2):117–21. 10.1097/00075198-200104000-00010PubMedCrossRef

16.

Reemst PH, van Goor H, Goris RJ: SIRS, MODS and tertiary peritonitis. Eur J Surg Suppl 1996, 576: 47–8. discussion 49PubMed

17.

Nathens AB, Rotstein OD, Marshall JC: Tertiary peritonitis: clinical features of a complex nosocomial infection. World J Surg 1998,22(2):158–63. 10.1007/s002689900364PubMedCrossRef

18.

Chromik AM, Meiser A, Holling J, et al.: Identification of patients at risk for development of tertiary peritonitis on a surgical intensive care unit. J Gastrointest Surg 2009,13(7):1358–67. 10.1007/s11605-009-0882-yPubMedCrossRef

19.

Menichetti F, Sganga G: Definition and classification of intra-abdominal infections. J Chemother 2009,21(Suppl 1):3–4.PubMedCrossRef

20.

Weigelt JA: Empiric treatment options in the management of complicated intra-abdominal infections. Cleve Clin J Med 2007,74(Suppl 4):S29–37.PubMedCrossRef

21.

Marshall JC, Innes M: Intensive care unit management of intra-abdominal infection. Crit Care Med 2003,31(8):2228–37. 10.1097/01.CCM.0000087326.59341.51PubMedCrossRef

22.

Herzog T, Belyaev O, Muller CA, et al.: Bacteribilia after preoperative bile duct stenting: a prospective study. J Clin Gastroenterol 2009,43(5):457–62. 10.1097/MCG.0b013e318186b19bPubMedCrossRef

23.

Roehrborn A, Thomas L, Potreck O, et al.: The microbiology of postoperative peritonitis. Clin Infect Dis 2001,33(9):1513–9. 10.1086/323333PubMedCrossRef

24.

Montravers P, Gauzit R, Muller C, et al.: Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis 1996,23(3):486–94. 10.1093/clinids/23.3.486PubMedCrossRef

25.

Burnett RJ, Haverstock DC, Dellinger EP, et al.: Definition of the role of enterococcus in intraabdominal infection: analysis of a prospective randomized trial. Surgery 1995,118(4):716–21. discussion 721–3 10.1016/S0039-6060(05)80040-6PubMedCrossRef

26.

Seguin P, Laviolle B, Chanavaz C, et al.: Factors associated with multidrug-resistant bacteria in secondary peritonitis: impact on antibiotic therapy. Clin Microbiol Infect 2006,12(10):980–5. 10.1111/j.1469-0691.2006.01507.xPubMedCrossRef

27.

Swenson BR, Metzger R, Hedrick TL, et al.: Choosing antibiotics for intra-abdominal infections: what do we mean by "high risk"? Surg Infect (Larchmt) 2009,10(1):29–39. 10.1089/sur.2007.041CrossRef

28.

Seguin P, Fedun Y, Laviolle B, et al.: Risk factors for multidrug-resistant bacteria in patients with post-operative peritonitis requiring intensive care. J Antimicrob Chemother 2010,65(2):342–6. 10.1093/jac/dkp439PubMedCrossRef

29.

Falagas ME, Karageorgopoulos DE: Extended-spectrum beta-lactamase-producing organisms. J Hosp Infect 2009,73(4):345–54. 10.1016/j.jhin.2009.02.021PubMedCrossRef

30.

Eagye KJ, Kim A, Laohavaleeson S, et al.: Surgical site infections: does inadequate antibiotic therapy affect patient outcomes? Surg Infect (Larchmt) 2009,10(4):323–31. 10.1089/sur.2008.053CrossRef

31.

Haddadin AS, Fappiano SA, Lipsett PA: Methicillin resistant Staphylococcus aureus (MRSA) in the intensive care unit. Postgrad Med J 2002,78(921):385–92. 10.1136/pmj.78.921.385PubMedCentralPubMedCrossRef

32.

Cainzos M: Review of the guidelines for complicated skin and soft tissue infections and intra-abdominal infections--are they applicable today? Clin Microbiol Infect 2008,14(Suppl 6):9–18.PubMedCrossRef

33.

Schneider CR, Buell JF, Gearhart M, et al.: Methicillin-resistant Staphylococcus aureus infection in liver transplantation: a matched controlled study. Transplant Proc 2005,37(2):1243–4. 10.1016/j.transproceed.2005.01.059PubMedCrossRef

34.

Hoban DJ, Bouchillon SK, Hawser SP, et al.: Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007–2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother 54(7):3031–4.

35.

Pitout JD, Laupland KB: Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008,8(3):159–66. 10.1016/S1473-3099(08)70041-0PubMedCrossRef

36.

Barie PS, Christou NV, Dellinger EP, et al.: Pathogenicity of the enterococcus in surgical infections. Ann Surg 1990,212(2):155–9. 10.1097/00000658-199008000-00007PubMedCentralPubMedCrossRef

37.

Nichols RL, Muzik AC: Enterococcal infections in surgical patients: the mystery continues. Clin Infect Dis 1992,15(1):72–6. 10.1093/clinids/15.1.72PubMedCrossRef

38.

Chatterjee I, Iredell JR, Woods M, Lipman J: The implications of enterococci for the intensive care unit. Crit Care Resusc 2007,9(1):69–75.PubMed

39.

Sitges-Serra A, Lopez MJ, Girvent M, et al.: Postoperative enterococcal infection after treatment of complicated intra-abdominal sepsis. Br J Surg 2002,89(3):361–7. 10.1046/j.0007-1323.2001.02023.xPubMedCrossRef

40.

de Vera ME, Simmons RL: Antibiotic-resistant enterococci and the changing face of surgical infections. Arch Surg 1996,131(3):338–42. 10.1001/archsurg.1996.01430150116021PubMedCrossRef

41.

Yellin AE, Heseltine PN, Berne TV, et al.: The role of Pseudomonas species in patients treated with ampicillin and Sulbactam for gangrenous and perforated appendicitis. Surg Gynecol Obstet 1985,161(4):303–7.PubMed

42.

Szeto CC, Kwan BC, Chow KM, et al.: Recurrent and relapsing peritonitis: causative organisms and response to treatment. Am J Kidney Dis 2009,54(4):702–10. 10.1053/j.ajkd.2009.04.032PubMedCrossRef

43.

Taccone FS, Rodriguez-Villalobos H, De Backer D, et al.: Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline. Eur J Clin Microbiol Infect Dis 2006,25(4):257–60. 10.1007/s10096-006-0123-1PubMedCrossRef

44.

Blot S, De Waele JJ: Critical issues in the clinical management of complicated intra-abdominal infections. Drugs 2005,65(12):1611–20. 10.2165/00003495-200565120-00002PubMedCrossRef

45.

Christou NV, Turgeon P, Wassef R, et al.: Management of intra-abdominal infections. The case for intraoperative cultures and comprehensive broad-spectrum antibiotic coverage. The Canadian Intra-abdominal Infection Study Group. Arch Surg 1996,131(11):1193–201. 10.1001/archsurg.1996.01430230075014PubMedCrossRef

46.

Inui T, Haridas M, Claridge JA, Malangoni MA: Mortality for intra-abdominal infection is associated with intrinsic risk factors rather than the source of infection. Surgery 2009,146(4):654–61. discussion 661–2 10.1016/j.surg.2009.06.051PubMedCrossRef

47.

Wacha H, Hau T, Dittmer R, Ohmann C: Risk factors associated with intraabdominal infections: a prospective multicenter study. Peritonitis Study Group. Langenbecks Arch Surg 1999,384(1):24–32. 10.1007/s004230050169PubMedCrossRef

48.

Nystrom PO, Bax R, Dellinger EP, et al.: Proposed definitions for diagnosis, severity scoring, stratification, and outcome for trials on intraabdominal infection. Joint Working Party of SIS North America and Europe. World J Surg 1990,14(2):148–58. 10.1007/BF01664867PubMedCrossRef

49.

Linden PK, Moellering RC Jr, Wood CA, et al.: Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin. Clin Infect Dis 2001,33(11):1816–23. 10.1086/323899PubMedCrossRef

50.

Ziglam H: Daptomycin and tigecycline: a review of clinical efficacy in the antimicrobial era. Expert Opin Pharmacother 2007,8(14):2279–92. 10.1517/14656566.8.14.2279PubMedCrossRef

51.

Van Laethem Y, Sternon J: Linezolid (Zyvoxid). Rev Med Brux 2004,25(1):47–50.PubMed

52.

Hasper D, Schefold JC, Baumgart DC: Management of severe abdominal infections. Recent Pat Antiinfect Drug Discov 2009,4(1):57–65. 10.2174/157489109787236265PubMedCrossRef

53.

Oliva ME, Rekha A, Yellin A, et al.: A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1–301-WW; ClinicalTrials.gov Identifier: NCT00081744]. BMC Infect Dis 2005, 5: 88. 10.1186/1471-2334-5-88PubMedCentralPubMedCrossRef

54.

Babinchak T, Ellis-Grosse E, Dartois N, et al.: The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005,41(Suppl 5):S354–67.PubMedCrossRef

55.

Fomin P, Beuran M, Gradauskas A, et al.: Tigecycline is efficacious in the treatment of complicated intra-abdominal infections. Int J Surg 2005,3(1):35–47. 10.1016/j.ijsu.2005.03.011PubMedCrossRef

56.

Sader HS, Jones RN, Dowzicky MJ, Fritsche TR: Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn Microbiol Infect Dis 2005,52(3):203–8. 10.1016/j.diagmicrobio.2005.05.002PubMedCrossRef

57.

Biedenbach DJ, Beach ML, Jones RN: In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases. Diagn Microbiol Infect Dis 2001,40(4):173–7. 10.1016/S0732-8893(01)00269-3PubMedCrossRef

58.

Lee C: Therapeutic challenges in the era of antibiotic resistance. Int J Antimicrob Agents 2008,32(Suppl 4):S197–9.PubMedCrossRef

59.

French GL: What's new and not so new on the antimicrobial horizon? Clin Microbiol Infect 2008,14(Suppl 6):19–29.PubMedCrossRef

60.

Dupont H: The empiric treatment of nosocomial intra-abdominal infections. Int J Infect Dis 2007,11(Suppl 1):S1–6.PubMedCrossRef

61.

Mazuski JE, Sawyer RG, Nathens AB, et al.: The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: evidence for the recommendations. Surg Infect (Larchmt) 2002,3(3):175–233. 10.1089/109629602761624180CrossRef

62.

Sandiumenge A, Diaz E, Rodriguez A, et al.: Impact of diversity of antibiotic use on the development of antimicrobial resistance. J Antimicrob Chemother 2006,57(6):1197–204. 10.1093/jac/dkl097PubMedCrossRef

63.

Kumar A, Roberts D, Wood KE, et al.: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006,34(6):1589–96. 10.1097/01.CCM.0000217961.75225.E9PubMedCrossRef

64.

Krobot K, Yin D, Zhang Q, et al.: Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 2004,23(9):682–7.PubMedCrossRef

65.

Kumar A, Ellis P, Arabi Y, et al.: Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009,136(5):1237–48. 10.1378/chest.09-0087PubMed

66.

Bodmann KF: Complicated intra-abdominal infections: pathogens, resistance. Recommendations of the Infectliga on antbiotic therapy. Chirurg 2010,81(1):38–49. 10.1007/s00104-009-1822-9PubMedCrossRef

67.

Sandiumenge A, Diaz E, Bodi M, Rello J: Therapy of ventilator-associated pneumonia. A patient-based approach based on the ten rules of "The Tarragona Strategy". Intensive Care Med 2003,29(6):876–83.PubMed

Title: Treatment of complicated intra-abdominal infections in the era of multi-drug resistant bacteria
Authors: T Herzog
AM Chromik
W Uhl
Publication date: 01-12-2010
Publisher: BioMed Central
Published in: European Journal of Medical Research / Issue 12/2010
Electronic ISSN: 2047-783X
DOI: https://doi.org/10.1186/2047-783X-15-12-525

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Treatment of complicated intra-abdominal infections in the era of multi-drug resistant bacteria

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2010

Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin

Multiresistant bacteria and current therapy - the economical side of the story

Nosocomial methicillin resistant Staphylococcus aureus pneumonia - epidemiology and trends based on data of a network of 586 German ICUs (2005-2009)

Complicated skin, skin structure and soft tissue infections - are we threatened by multi-resistant pathogens?

Pharmaco-economic evaluation of antibiotic therapy strategies in DRG-based healthcare systems - a new approach

Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin